{
    "id": 5750,
    "name": "uterine corpus serous adenocarcinoma",
    "source": "DOID",
    "definition": "A uterine corpus cancer that is characterized histologically by papillae with fibrovascular cores,  marked nuclear atypia, psammoma bodies and cilia. [url:http\\://en.wikipedia.org/wiki/Uterine_serous_carcinoma]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:5750",
    "evidence": [
        {
            "id": 7638,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-expressing primary uterine serous carcinoma (USC) cell lines in culture, including cell lines with both high and low levels of ERBB2 (HER2) expression, and inhibited tumor growth and improved survival in ERBB2 (HER2)-expressing USC primary cell line xenografts (PMID: 27256376).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 4539,
                "therapyName": "SYD985",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6448,
                    "pubMedId": 27256376,
                    "title": "SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7644,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYD895 induced cell death in ERBB2 (HER2)-amplified primary uterine serous carcinoma (USC) cell lines in culture and inhibited tumor growth and improved survival in ERBB2 (HER2)-amplified USC primary cell line xenografts (PMID: 27256376).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 4539,
                "therapyName": "SYD985",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6448,
                    "pubMedId": 27256376,
                    "title": "SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27256376"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9059,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Nerlynx (neratinib) in culture, resulting in inhibition of cell growth (PMID: 26333383).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9061,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification demonstrated sensitivity to treatment with Taselisib (GDC-0032) in culture, resulting in inhibition of cell growth (PMID: 26333383).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9062,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) resulted in a synergistic effect, demonstrating greater cell growth inhibitory activity in uterine serous carcinoma cells harboring ERBB2 (HER2) amplification compared to either agent alone (PMID: 26333383).",
            "molecularProfile": {
                "id": 531,
                "profileName": "ERBB2 amp"
            },
            "therapy": {
                "id": 4871,
                "therapyName": "Neratinib + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9063,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Taselisib (GDC-0032) did not result in delay of cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, however, did result in tumor growth inhibition in xenograft models (PMID: 26333383).",
            "molecularProfile": {
                "id": 26704,
                "profileName": "ERBB2 amp PIK3CA wild-type"
            },
            "therapy": {
                "id": 1016,
                "therapyName": "Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9064,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nerlynx (neratinib) delayed cell cycle activity during treatment of a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture, and inhibited tumor growth in xenograft models (PMID: 26333383).",
            "molecularProfile": {
                "id": 26704,
                "profileName": "ERBB2 amp PIK3CA wild-type"
            },
            "therapy": {
                "id": 828,
                "therapyName": "Neratinib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9065,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Taselisib (GDC-0032) and Nerlynx (neratinib) delayed cell cycle activity in a uterine serous carcinoma cell line harboring PIK3CA wild-type and ERBB2 (HER2) amplification in culture (PMID: 26333383).",
            "molecularProfile": {
                "id": 26704,
                "profileName": "ERBB2 amp PIK3CA wild-type"
            },
            "therapy": {
                "id": 4871,
                "therapyName": "Neratinib + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9067,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Nerlynx (neratinib) and Taselisib (GDC-0032), compared to either agent alone, resulted in greater inhibition of cell cycle activity in a uterine serous carcinoma cell line harboring ERBB2 (HER2) amplification and a PIK3CA mutation in culture, and in xenograft models, showed increased tumor growth inhibition and tumor regression (PMID: 26333383).",
            "molecularProfile": {
                "id": 19124,
                "profileName": "ERBB2 amp PIK3CA mut"
            },
            "therapy": {
                "id": 4871,
                "therapyName": "Neratinib + Taselisib",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6891,
                    "pubMedId": 26333383,
                    "title": "Dual HER2/PIK3CA Targeting Overcomes Single-Agent Acquired Resistance in HER2-Amplified Uterine Serous Carcinoma Cell Lines In Vitro and In Vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26333383"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15074,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-5829 inhibited proliferation of uterine corpus serous adenocarcinoma (uterine serous carcinoma) cell lines overexpressing Myc in culture, reduced Myc expression and suppressed tumor growth in cell line xenograft animal models (PMID: 29941483).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 5276,
                "therapyName": "GS-5829",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12623,
                    "pubMedId": 29941483,
                    "title": "Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29941483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15075,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GS-626510 inhibited proliferation and Myc expression, induced apoptosis in uterine corpus serous adenocarcinoma (uterine serous carcinoma) cell lines overexpressing Myc in culture, and suppressed tumor growth in cell line xenograft animal models (PMID: 29941483).",
            "molecularProfile": {
                "id": 4715,
                "profileName": "MYC over exp"
            },
            "therapy": {
                "id": 7414,
                "therapyName": "GS-626510",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12623,
                    "pubMedId": 29941483,
                    "title": "Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29941483"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18602,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Combination Paraplatin (carboplatin), Taxol (paclitaxel), and Herceptin (trastuzumab) is in guidelines for ERBB2 (HER2)-positive patients with advanced and recurrent uterine serous carcinoma (NCCN.org).",
            "molecularProfile": {
                "id": 1187,
                "profileName": "ERBB2 positive"
            },
            "therapy": {
                "id": 1887,
                "therapyName": "Carboplatin + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 5750,
                "name": "uterine corpus serous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT01367002",
            "title": "Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 947,
                    "therapyName": "Trastuzumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02491099",
            "title": "A Phase II Evaluation of Afatinib",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 623,
                    "therapyName": "Afatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03660826",
            "title": "Olaparib and Cediranib Maleate in Treating Patients With Recurrent, Refractory, or Metastatic Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 1971,
                    "therapyName": "Cediranib + Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03668340",
            "title": "A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 822,
                    "therapyName": "Adavosertib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03694262",
            "title": "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7499,
                    "therapyName": "Atezolizumab + Bevacizumab + Rucaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03832361",
            "title": "Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer",
            "phase": "Phase II",
            "recruitment": "Not yet recruiting",
            "therapies": [
                {
                    "id": 3232,
                    "therapyName": "Mirvetuximab Soravtansine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03914612",
            "title": "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 2103,
                    "therapyName": "Carboplatin + Paclitaxel + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 1124,
                    "therapyName": "Carboplatin + Paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04080284",
            "title": "Trial of Maintenance With Niraparib- Uterine Serous Carcinoma",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 832,
                    "therapyName": "Niraparib",
                    "synonyms": null
                }
            ]
        }
    ]
}